DIAGNOSTIC ASPECTS OF PAGET’S DISEASE OF BONE IN CLINICAL PRACTICE
https://doi.org/10.14412/1995-4484-2017-690-697
Abstract
Paget’s disease of bone (PDB) is a chronic localized skeletal disease that belongs to a group of metabolic osteopathies and is characterized by impaired bone remodeling to form foci of increased bone resorption followed by replacement with an excessive amount of defective, less durable bone that is prone to deformities and pathologic fractures. The course of PDB shows three stages: rarefaction, compaction, and coarse-trabecular remodeling – each of which is characterized by certain clinical, biochemical, and radiological manifestations. The majority of the clinical manifestations of the disease are associated with skeletal injury. The disease is characterized by the appearance of bone and joint pain in case of secondary osteoarthritis, bone deformities, pathological fractures, hearing loss due to damage to the skull bones, etc. In many patients, the disease is asymptomatic and detected incidentally after finding a high serum alkaline phosphatase activity or during bone X-ray for any pathological processes, but it can be diagnosed fairly late in the development of complications, as shown in the clinical examples. A combination of clinical, biochemical, morphological data and radiological findings allows for a diagnosis. The use of bisphosphonates is the method of choice for the treatment of PDB.
About the Authors
I. B. Bashkova
I.N. Ulyanov Chuvash State University, Cheboksar;
Federal Center for Traumatology, Orthopedics, and Endoprosthesis, Ministry of Health of Russia, Cheboksary
Russian Federation
Russian Federation
N. S. Nikolaev
I.N. Ulyanov Chuvash State University, Cheboksar;
Federal Center for Traumatology, Orthopedics, and Endoprosthesis, Ministry of Health of Russia, Cheboksary
Russian Federation
Russian Federation
N. V. Bezlyudnaya
Federal Center for Traumatology, Orthopedics, and Endoprosthesis, Ministry of Health of Russia, Cheboksary
Russian Federation
Russian Federation
V. A. Kichigin
I.N. Ulyanov Chuvash State University, Cheboksar
Russian Federation
Russian Federation
References
1. Paget J. On a form of chronic inflammation of bone (osteitis deformans). Trans R Med Chir Soc. 1877;60:37-64.
2. doi: 10.1177/095952877706000105
3. Рожинская ЛЯ. Болезнь Педжета. Остеопороз и остеопатии. 2007;(2):29-31 [Rozhinskaya LYa. Paget’s Disease. Osteoporoz i Osteopatii = Osteoporosis and Osteopathy. 2007;(2):29-31 (In Russ.)].
4. Бунчук НВ. Ревматические заболевания пожилых (Избраннoе). Москва: МЕДпресс-информ; 2010. С. 220-57 [Bunchuk NV. Revmaticheskie zabolevaniya pozhilykh (Izbrannoe) [Rheumatic diseases of the elderly (Elected)]. Moscow: MEDpress-inform; 2010. P. 220-57].
5. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget’s disease of bone. Lancet. 2008;372:155-63. doi: 10.1016/S0140-6736(08)61035-1
6. Корсакова ЮЛ. Болезнь Педжета: современные методы лечения. Современная ревматология. 2010;4(2):11-17. [Korsakova YL. Paget’s Disease: modern treatment methods. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2010;4(2):11-17. (In Russ.)]. doi: 10.14412/1996-7012-2010-596
7. Nebot Valenzuela E, Pietschmann P. Epidemiology and pathology of Paget’s disease of bone – a review. Wien Med Wochenschr. 2017;67(1-2):2-8. doi: 10.1007/s10354-016-0496-4
8. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest. 2005;115:200-8. doi: 10.1172/JCI24281
9. Alonso N, Calero-Paniagua I, Pino-Montes J. Clinical and genetic advances in Paget’s disease of bone: a review. Clin Rev Bone Miner Metab. 2017;15(1):37-48. doi: 10.1007/s12018-016-9226-0
10. Singer FR, Bone HG, Hosking DJ, et al. Paget’s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(12):4408-22. doi: 10.1210/jc.2014-2910
11. Monsell EM. The mechanism of hearing loss in Paget’s disease of bone. Laryngoscope. 2004;114:598-606. doi: 10.1097/00005537-200404000-00002
12. Braun RA, Milito CF, Goldman SM, Fernandes EA. Ivory vertebra: imaging findings in different diagnoses. Radiol Bras. 2016;49(2):117-21. doi: 10.1590/0100-3984.2014.0103
13. Kang H, Park YC, Yang KH. Paget’s disease: skeletal manifestations and effect of bisphosphonates. J Bone Metab. 2017;24(2):97-103. doi: 10.11005/jbm.2017.24.2.97
14. Родионова СС, Колондаев АФ. Болезнь Педжета. Москва: ГЭОТАР-Медиа; 2008. 56 с. [Rodionova SS, Kolondaev AF. Bolezn' Pedzheta [Paget’s Disease]. Moscow: GEOTAR-Media; 2008. 56 p.].
15. Melton LJ 3rd, Tiegs RD, Atkinson EJ, O’Fallon WM. Fracture risk among patients with Paget’s disease: a population-based cohort study. J Bone Miner Res. 2000;15(11):2123-8. doi: 10.1359/jbmr.2000.15.11.2123
16. Кутин АА. Поздняя диагностика болезни Педжета. Клиническая практика. 2010;2(2):37-40. [Kutin AA. Late diagnosis of Paget’s disease. Klinicheskaya Praktika = Clinical Practice. 2010;2(2):37-40 (In Russ.)].
17. Башкова ИБ, Безлюдная НВ, Карпухин АС и др. Костная болезнь Педжета в практике врача травматолога-ортопеда. Остеопороз и остеопатии. 2016;(2):108. [Bashkova IB, Bezlyudnaya NV, Karpukhin AS, et al. Paget’s Disease in the practice of a traumatologist-orthopedist. Osteoporoz i Osteopatii = Osteoporosis and Osteopathy. 2016;(2):108 (In Russ.)].
18. Злобина ТИ, Толстых АА, Калягин АН. Болезнь Педжета. Современные проблемы ревматологии. 2012;4(4):182-8 [Zlobina TI, Tolstykh AA, Kalyagin AN. Paget’s Disease. Sovremennye Problemy Revmatologii = Modern Problems of Rheumatology. 2012;4(4):182-8 (In Russ.)].
19. Горячев АН, Резник ЛБ, Тютюнников АВ, Турушев МА. Нерешенные вопросы лечения деформирующей остеодистрофии (болезнь Педжета). Гений ортопедии. 2009;(3):90-3 [Goryachev AN, Reznick LB, Tyutyunnikov AV, Turushev MA. Unresolved issues of treatment of deforming osteodystrophy (Paget’s Disease). Genii Ortopedii = The Genius of Orthopedics. 2009;(3):90-3 (In Russ.)].
20. Hultgren HN. Osteitis deformans (Paget’s disease) and calcific disease of the heart valves. Am J Cardiol. 1998;81:1461-4.
21. doi: 10.1016/S0002-9149(98)00213-6
22. Laroche M, Delmotte A. Increased arterial calcification in Paget’s disease of bone. Calcif Tissue Int. 2005;77:129-33. doi: 10.1007/s00223-005-0250-1
23. Morales-Piga AA, Moya JL, Bachiller FJ, et al. Assessment of cardiac function by echocardiography in Paget’s disease of bone. Clin Exp Rheumatol. 2000;18:31-7.
24. Franck WA, Bress NM, Singer FR, et al. Rheumatic manifestations of Paget’s disease of bone. Am J Med. 1974;56:592-603. doi: 10.1016/0002-9343(74)90629-9
25. Altman RD. Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum. 1980;2:1121-7. doi: 10.1002/art.1780231008
26. Deyrup AT, Montag AG, Inwards CY, et al. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med. 2007;131:942-6.
27. Mangham DC, Davie MW, Grimer RJ. Sarcoma arising in Paget’s disease of bone: declining incidence and increasing age at presentation. Bone. 2009;44(3):431-6. doi: 10.1016/j.bone.2008.11.002
28. Gebhart M, Vandeweyer E, Nemec E. Paget’s disease of bone complicated by giant cell tumor. Clin Orthop Relat Res. 1998;352:187-93. doi: 10.1097/00003086-199807000-00022
29. Rendina D, Mossetti G, Soscia E, et al. Giant cell tumor and Paget’s disease of bone in one family: geographic clustering. Clin Orthop Relat Res. 2004;421:218-24. doi: 10.1097/00000118702.46373.e3
30. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809. doi: 10.1056/NEJMoa074941
31. Hosking D. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22:142-8. doi: 10.1359/jbmr.061001
32. Tziomalos K. Persistent effect of zoledronic acid in Paget’s disease. Clin Exp Rheumatol. 2007;25:464-6.
33. Cundy T, Maslowski K, Grey A, Reid IR. Durability of response to zoledronate treatment and competing mortality in Paget’s disease of bone. J Bone Miner Res. 2017;32(4):753-6. doi: 10.1002/jbmr.3029
34. Tucci JR. Zoledronic acid therapy of patients with Paget disease of bone resistant to or with unsustained remission following prior bis-phosphonate therapy. Endocr Pract. 2015;21(10):1111-6.
35. doi: 10.4158/EP15664
36. Elshafie O, Alsaffi N, Hussain S, Woodhouse N. Paget’s disease in an Omani: long-term improvement following a single injection of zoledronic acid. Oman Med J. 2016;31(2):146-9. doi: 10.5001/omj.2016.28
37. Baykan EK, Saygili LF, Erdogan M, et al. Efficacy of zoledronic acid treatment in Paget disease of bone. Osteoporos Int. 2014;25(9):2221-3. doi: 10.1007/s00198-014-2752-z
38. Reid IR, Brown JP, Levitt N, et al. Re-treatment of relapsed Paget’s disease of bone with zoledronic acid: results from an open-label study. Bonekey Rep. 2013;6:442. doi: 10.1038/bonekey.2013.176
39. Hanna SA, Dawson-Bowling S, Millington S, et al. Total hip arthroplasty in patients with Paget’s disease of bone: a systematic review. World J Orthop. 2017;8(4):357-63. doi: 10.5312/wjo.v8.i4.357
Review
For citations:
Bashkova I.B., Nikolaev N.S., Bezlyudnaya N.V., Kichigin V.A. DIAGNOSTIC ASPECTS OF PAGET’S DISEASE OF BONE IN CLINICAL PRACTICE. Rheumatology Science and Practice. 2017;55(6):690-697. (In Russ.) https://doi.org/10.14412/1995-4484-2017-690-697
Views:
1697
Email this article 